ACE inhibitors exert beneficial cardiovascular effects through novel mechanisms, including accumulation of N-acetyl-seryl-aspartyl-lysyl-proline and activation of an ACE signaling cascade.
Inhibition of the angiotensin-converting enzyme (ACE) protects against the progression of several cardiovascular diseases. Because of its dual role in regulating angiotensin II and bradykinin levels, the positive clinical effects of ACE inhibitors were thought to be the consequence of concomitant reductions in the production of angiotensin II and the degradation of bradykinin. Recent evidence suggests that some of the beneficial effects of ACE inhibitors on cardiovascular function and homeostasis can be attributed to novel mechanisms. These include the accumulation of the ACE substrate N -acetyl-seryl-aspartyl-lysyl-proline, which blocks collagen deposition in the injured heart, as well as the activation of an ACE signaling cascade that involves the activation of the kinase CK2 and the c-Jun N-terminal kinase in endothelial cells and leads to changes in gene expression. Moreover, at least one other ACE homologue (ACE2) is proposed to counteract the detrimental effects associated with the activation of the classical renin-angiotensin system. These data reveal hitherto unexpected levels of internal regulation of the renin-angiotensin system.
Ingrid Fleming (Thu,) conducted a review in Cardiovascular diseases. ACE inhibitors was evaluated. ACE inhibitors exert beneficial cardiovascular effects through novel mechanisms, including accumulation of N-acetyl-seryl-aspartyl-lysyl-proline and activation of an ACE signaling cascade.